VivoSeq
Oncology

Locally Advanced Unresectable or Metastatic Solid Tumors

1

Pipeline Programs↗

5

Active Trials↗

2

Companies Involved↗

Locally Advanced Unresectable or Metastatic Solid Tumors is an early-stage landscape with 1 program across 2 companies. The most active players are Hangzhou Sumgen Biotech Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd..

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hangzhou Sumgen Biotech Co., Ltd.

1 program

Phase 1Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

SG1906

Hangzhou Sumgen Biotech Co., Ltd.

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

5

clinical trials

Recruiting4 · 80%
Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Recruiting·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05458219·470 enrolled
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Recruiting·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT05636215·368 enrolled
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Active, not recruiting·RRemeGen Co., Ltd.·Phase 1·NCT05867303·48 enrolled
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
Recruiting·RRemeGen Co., Ltd.·Phase 1/2·NCT06038396·48 enrolled
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.
Recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 1·NCT05857332·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)